Of the world's population, 7.5% report having lower back pain, and eight out of 10 people in the U.S. will experience it in their lifetime. With no long-term treatment options other than surgery, most of these patients continue to suffer.
A leading Eastern European CRO OCT Clinical partnered with a Sweden-based pharmaceutical company called Stayble Therapeutics to run a Phase 2b study in three countries in Europe. This is a multicenter, randomized study, the primary goal of which is to evaluate the efficacy of the study medicine vs. placebo. The study is double-blinded, which means that neither the patient nor the treating physician knows whether the patient is receiving a high or low dose of STA363—the medicine under study—or a placebo. All trial participants are followed up for 12 months.
Download the full text to learn more about this study’s outcomes.